Rituximab capping triggers intracellular reorganisation of B cells
The antibody rituximab, which binds to the protein CD20 on the surface of B-cells, has been used to treat B-cell malignancies for several years. However, the molecular mechanisms underlying this treatment are not yet fully understood. One well-established rituximab-induced mechanism, natural killer...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Science Matters
2017
|